OptimizeRx
OPRX
87 hedge funds and large institutions have $102M invested in OptimizeRx in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 27 reducing their positions, and 17 closing their positions.
84% more capital invested
Capital invested by funds: $55.3M → $102M (+$46.4M)
1.74% more ownership
Funds ownership: 61.72% → 63.47% (+1.7%)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding
Funds holding: 87 → 87 (0)
11% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 27
61% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $2.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$1.79M |
| 3 |
WCA
Whetstone Capital Advisors
Shawnee Mission,
Kansas
|
+$965K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$746K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$713K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$783K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$741K |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$707K |
| 4 |
GIPM
G2 Investment Partners Management
New York
|
-$647K |
| 5 |
AE
AMH Equity
Great Neck,
New York
|
-$608K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Group One Trading
Chicago,
Illinois
| – | -$38.2K | -6,244 | Closed |
|
|
CT
102
Colonial Trust
Spartanburg,
South Carolina
| – | -$2.7K | -512 | Closed |
|
|
AAP
103
Arax Advisory Partners
Denver,
Colorado
| – | -$613 | -126 | Closed |
|
|
FMII
104
Farmers & Merchants Investments Inc
Lincoln,
Nebraska
| – | -$58 | -12 | Closed |
|
OPRX Hedge Fund Activity: Q1 2025 in Review
87 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q1 2025, worth a combined $102M — up 84% from $55.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new OPRX positions and 17 closed out — a net gain of 1 holder — while 24 added to existing stakes and 27 trimmed.
The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $2.9M. The largest seller was Walleye Capital, cutting an estimated $783K.
- 87 institutional investors held OptimizeRx (OPRX) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $102M of OptimizeRx stock for Q1 2025, up 84% quarter-over-quarter.
- 18 funds opened new OptimizeRx positions in Q1 2025 and 17 closed out, a net change of +1 holder.
- The largest OptimizeRx buyer in Q1 2025 was Parkman Healthcare Partners, an estimated $2.9M added.
- The largest OptimizeRx seller in Q1 2025 was Walleye Capital, an estimated $783K sold.
Based on aggregated 13F filings for Q1 2025.